CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 407 enrolled
Drug / intervention
semaglutide 2.4 mg +1 moredrug
Likely dose
semaglutide 2.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05064735
NCT05064735Phase 3Completed

Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis

Novo Nordisk A/S·interventional·Posted Oct 1, 2021·Updated Nov 17, 2025

In Brief

A Phase 3 clinical trial evaluating semaglutide 2.4 mg and semaglutide 2.4 mg (placebo) for Obesity. Completed, enrolled 407 participants across 122 sites in 11 countries.

Detailed Summary

This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study, participants will have talks with study staff about how to eat healthy food and how to be more physically active. The study will last for about 1 ½ years. Participants will have 14 clinic visits with the study staff. At the first clinic visit participants will have a blood sample taken. Participants will have an X-ray of participants knee taken at the first visit. If participants have had an X-ray recently, this may not be needed. At 6 of the clinic visits participants cannot take pain medications for 3 days before the visit. Participants cannot take part if participants have had a joint replacement surgery in participants knee. Participants cannot take part if participants have or have had diabetes. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesCanada, Colombia, Denmark, France, Norway, Russia, Saudi Arabia, South Africa, Spain, Sweden, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedOct 1, 2021
Enrollment StartOct 1, 2021
Primary CompletionJul 24, 2023
Study CompletionSep 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.8 years ago

Interventions

semaglutide 2.4 mgdrug

semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity

semaglutide 2.4 mg (placebo)drug

semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity